Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Treatment-free remission and relapse in chronic myeloid leukaemia (CML) patients

ABSTRACT: Peripheral blood from 70 individuals (31 CML patients who subsequently relapsed after discontinuation of tyrosine kinase inhibitors (TKI) treatment, 29 CML patients who maintained treatment-free remission, and 10 healthy donors) was profiled to investigate transcriptional programs associated with sustained control versus relapse. Samples from CML patients were collected on the last day of TKI treatment within the EURO-SKI trial, and leukocytes were isolated for RNA extraction. Genome-wide expression profiling was performed using Clariom D microarrays (Applied Biosystems). The resulting dataset aims to define peripheral blood molecular signatures and biomarkers that predict treatment-free remission in CML.

ORGANISM(S): Homo sapiens

SUBMITTER: Petr Nazarov

PROVIDER: E-MTAB-16324 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Genomic profiling of immature hematopoietic cells to obtain insights into imatinib resistance

Project description:Chronic myeloid leukemia (CML) epitomizes successful targeted therapy, with 86% of patients in the chronic phase treated with tyrosine kinase inhibitors (TKIs) attaining remission. However, resistance to TKIs occurs during treatment, and patients with resistance to TKIs progress to the acute phase called Blast Crisis (BC), wherein the survival is restricted to 7-11 months. About 80 % of patients in BC are unresponsive to TKIs. This issue can be addressed by identifying a molecular signature which can predict resistance in CML-CP prior to treatment as well as by delineating the molecular mechanism underlying resistance. Herein, we report genomic analysis of CML patients and imatinib-resistant K562 cell line to achieve the same. Thirteen CML patients (sensitive and resistant to TKIs) and 2 BMT donors (as control) were recruited for the study. DNA was isolated from an enriched CD34+ fraction for each sample as well as from K562 cells made resistant to imatinib which provided a model system for further molecular investigations. DNA was subjected to Cytoscan HD array (Affymatrix) analysis from patient samples and cell lines. Affymetrix CytoScan™ HD array (Applied Biosystems™, Cat# 901835) chip consists of 2.6 M oligonucleotide probes across the genome, including 1953K unique non-polymorphic probes and 750K bi-allelic SNP (single nucleotide polymorphism) probes. Our study identified accumulation of aberrations on chromosomes 1, 3, 7, 16 and 22 as predictive of occurrence of resistance. Further, recurrent amplification in chromosomal region 8q11.2-12.1 was detected in highly resistant K562 cells as well as CML patients. The genes present in this region were analyzed to understand molecular mechanism of imatinib resistance.

2024-01-01 | E-MTAB-11899 | biostudies-arrayexpress

Adaptive Metabolic Response to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukemia Stem Cells

Project description:Tyrosine kinase inhibitors (TKI) are highly effective in treating chronic myelogenous leukemia (CML), but primitive, quiescent CML stem cells persist as a source for recurrence. The effects of TKI treatment on CML stem cell metabolism, and the role of metabolic reprogramming in CML stem cell persistence after TKI treatment are not clear. Here we show that TKI treatment in a CML mouse model leads to acute inhibition of aerobic glycolysis, glutaminolysis, TCA cycle and oxidative phosphorylation (OXPHOS) in CML progenitor cells, but that these pathways are restored with continued TKI treatment. Single cell analysis reveals that primitive CML stem cell subpopulations characterized by lower OXPHOS, glycolysis, nucleotide metabolism, and MYC gene signatures are enriched after TKI treatment. TKI treatment initially results in broad inhibition of energy metabolism gene signatures, but continued treatment leads to metabolic reprogramming in persistent stem cells, with enhanced OXPHOS and MYC gene signatures. TKI treatment enhanced HIF-1 activity in quiescent CML stem cells, and addition of a HIF-1 inhibitor significantly depleted CML stem cells in TKI-treated mice. Our results identify mechanisms of metabolic adaptation in CML stem cells following TKI treatment, which can be targeted to deplete persistent quiescent CML stem cells.

2023-08-30 | GSE207346 | GEO

State-transition Modeling of Blood Transcriptome Predicts Disease Evolution and Treatment Response in Chronic Myeloid Leukemia (CML)

Project description:Chronic myeloid leukemia (CML) is initiated and initially maintained solely by the fusion gene BCR-ABL, encoding a mutant protein targeted in the clinic with tyrosine kinase inhibitors (TKIs) While TKI treatment is effective in inducing long-term remission, frequently is not curative. For these reasons, CML is an ideal disease to test our hypothesis that that transcriptome-based state-transition models accurately predict cancer evolution and treatment response. We hypothesized that transcriptome-based state-transition models accurately predict cancer evolution and treatment response.

2023-11-02 | GSE244990 | GEO

Differentially Expressed Proteins in Plasma-Derived Extracellular Vesicles from Chronic Myeloid Leukemia Patients

Project description:Chronic myeloid leukemia (CML) is driven by the BCR::ABL1 fusion gene. Although tyrosine kinase inhibitors (TKIs) have transformed outcomes, treatment resistance persists. Plasma extracellular vesicles (EVs) reflect their cell of origin and may serve as stable biomarkers. To characterize the plasma EV proteome in CML patients with distinct treatment responses and T315I mutation status. EVs were isolated from the plasma of healthy controls (HC) and CML patients classified as good (GTR) or poor (PTR) treatment responders, treatment-free remission (TFR), and T315I or pre-T315I mutation carriers. EVs were purified by size-exclusion chromatography, characterized by NTA and TEM, and analyzed by label-free mass spectrometry, followed by differential expression, enrichment, and protein–protein interaction analyses. A total of 598 proteins were identified, 257 retained after quality and abundance filtering. Forty-two proteins were differentially expressed among HC, GTR, and PTR groups (p < 0.01), with PTR samples showing marked downregulation of cytoskeletal and chaperone proteins (such as MYH9, HSP90AB1, FERMT3). TFR patients exhibited distinct enrichment in complement and coagulation cascades (C3, C4B, F9, F11) and metabolic pathways. Plasma EV proteomes reflect CML clinical status, revealing immune and cytoskeletal alterations associated with treatment response, remission, and resistance, suggesting potential biomarkers for disease monitoring.

2026-01-26 | PXD071200 | Pride

The effect of IM and MSC treatment on gene expression in CML CD34+ cells

Project description:Tyrosine kinase inhibitors (TKI) are highly effective in treatment of chronic myeloid leukemia (CML) but do not eliminate leukemia stem cells (LSC), which remain a potential source of relapse. TKI treatment effectively inhibits BCR-ABL kinase activity in CML LSC, suggesting that additional kinase-independent mechanisms contribute to LSC preservation. We investigated whether signals from the bone marrow (BM) microenvironment protect CML LSC from TKI treatment. Coculture with human BM mesenchymal stromal cells (MSC) significantly inhibited apoptosis and preserved CML stem/progenitor cells following TKI exposure, maintaining colony forming ability and engraftment potential in immunodeficient mice. We found that the N-Cadherin receptor plays an important role in MSC-mediated protection of CML progenitors from TKI. N-Cadherin-mediated adhesion to MSC was associated with increased cytoplasmic N-Cadherin-β-catenin complex formation, as well as enhanced β-catenin nuclear translocation and transcriptional activity. Increased exogenous Wnt-mediated β-catenin signaling played an important role in MSC-mediated protection of CML progenitors from TKI treatment. Our results reveal a close interplay between N-Cadherin and the Wnt-β-catenin pathway in protecting CML LSC during TKI treatment. Importantly, these results reveal novel mechanisms of resistance of CML LSC to TKI treatment, and suggest new targets for treatment designed to eradicate residual LSC in CML patients.

2013-01-01 | GSE43225 | GEO

Microarray analysis of macrophages derived from mouse bone marrow cells with or without metformin treatment

Project description:In this study, we investigated the effects of metformin on the differentiation of bone marrow-derived macrophages (BMDMs) and their potential role in cancer immunity. BMDMs were generated from bone marrow cells extracted from C57BL/6N mice and differentiated in the presence or absence of metformin. Our transcriptomic analysis, performed using the Clariom S Mouse microarrays, revealed changes in gene expression profiles between metformin-treated and untreated macrophages.

2025-06-13 | E-MTAB-14199 | biostudies-arrayexpress

Mutation Detection in p210 kinase domain

Project description:Mutations in the BCR-ABL1 kinase domain (BCR-ABL1 KD) are among the most common causes of tyrosine kinase inhibitor (TKI) resistance in patients with chronic myeloid leukemia (CML). High-throughput DNA sequencing targeting the BCR-ABL1 KD revealed a higher frequency of mutations in patients with short treatment-free remission (TFR) compared to those with long TFR.

2025-11-12 | GSE304892 | GEO

A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors

Project description:The uploaded datasets contains raw data from our research: columns represent patients, rows represent meta data (patients response, type of sarcoma, etc ...) + the raw gene counts.

2022-09-01 | E-MTAB-12163 | biostudies-arrayexpress

Metabolic alterations mediated by STAT3 promotes drug persistence in CML [K562 bulk RNA-Seq]

Project description:Leukemic stem cells (LSCs) can acquire non-mutational resistance following drug treatment leading to therapeutic failure and relapse. However, oncogene-independent mechanisms of drug persistence in LSCs are incompletely understood, which is the primary focus of this study. We integrated proteomics, transcriptomics, and metabolomics to determine the contribution of STAT3 in promoting metabolic changes in tyrosine kinase inhibitor (TKI) persistent chronic myeloid leukemia (CML) cells. Proteomic and transcriptional differences in TKI persistent CML cells revealed BCR-ABL-independent STAT3 activation in these cells. While knockout of STAT3 inhibited the CML cells from developing drug-persistence, inhibition of STAT3 using a small molecule inhibitor sensitized the persistent CML cells to TKI treatment. Interestingly, given the role of phosphorylated STAT3 as a transcription factor, it localized uniquely to genes regulating metabolic pathways in the TKI-persistent CML stem and progenitor cells. Subsequently, we observed that STAT3 dysregulated mitochondrial metabolism forcing the TKI-persistent CML cells to depend on glycolysis, unlike TKI-sensitive CML cells, which are more reliant on oxidative phosphorylation. Finally, targeting pyruvate kinase M2, a rate-limiting glycolytic enzyme, specifically eradicated the TKI-persistent CML cells. By exploring the role of STAT3 in altering metabolism, we provide critical insight into identifying potential therapeutic targets for eliminating TKI-persistent LSCs.

2021-07-06 | GSE174800 | GEO